Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.93%
Tags
FAQ
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
Supernus Pharmaceuticals (SUPN) last closed at $42.67.
What is the market cap of Supernus Pharmaceuticals (SUPN)?
The market cap of Supernus Pharmaceuticals (SUPN) is approximately $2.5B.